Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide

Nephrology Dialysis Transplantation

Volumn 32, Issue 8, 2017, Pages 1363-1372

  Covic, Adrian C ^a   Floege, Jürgen ^b   Ketteler, Markus ^c   Sprague, Stuart M ^d   Lisk, Laura ^e   Rakov, Viatcheslav ^e   Rastogi, Anjay ^f  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c KfH Kidney Center Coburg   (Germany)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^e Vifor (International) Inc   (Switzerland)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chronic kidney disease; dialysis; iron; phosphate binder; sucroferric oxyhydroxide

Indexed keywords

ALUMINUM DERIVATIVE; ANTIANEMIC AGENT; CALCIUM DERIVATIVE; FERRITIN; HEMOGLOBIN; IRON; LANTHANUM; PHOSPHATE BINDING AGENT; SEVELAMER CARBONATE; SUCROFERRIC OXYHYDROXIDE; TRANSFERRIN; FERRIC ION; SUCROSE;

ADULT; ANEMIA; ARTICLE; CHEMICAL PARAMETERS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG USE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG COMBINATION; HEMODIALYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

DRUG COMBINATIONS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; IRON; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; SUCROSE;

EID: 85026855117     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw242     Document Type: Article

References (27)

1. Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 280-289
2. Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014; 86: 638-647
3. Floege J, Covic AC, Ketteler M, et al. Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 2015; 30: 1037-1046
4. Sprague SM, Covic A, Floege J, et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21. Presented at: National Kidney Foundation, Las Vegas, NV, USA, 22-26 April 2014
5. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: The role of inflammation. Clin J Am Soc Nephrol 2008; 3: 1691-1701
6. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149
7. Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 2003; 42: 864-881
8. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634
9. Canavesi E, Alfieri C, Pelusi S, et al. Hepcidin and HFE protein: Ironmetabolism as a target for the anemia of chronic kidney disease. World J Nephrol 2012; 1: 166-176
10. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: Relevance for dialysis patients. Nephrol Dial Transplant 2014; 29: 255-259
11. Singh N, Agarwal AK. Pumping iron: Revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease. Clin Nephrol 2012; 77: 188-194
12. Bailie GR, Larkina M, Goodkin DA, et al. Variation in intravenous iron use internationally and over time: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28: 2570-2579
13. Pisoni RL, Fuller DS, Bieber BA, et al. The DOPPS practice monitor for US dialysis care: Trends through August 2011. Am J Kidney Dis 2012; 60: 160-165
14. Vaziri ND. Understanding iron: Promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000
15. Wilhelm M, Gaillard S, Rakov V, et al. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol 2014; 81: 251-258
16. Cozzolino M, Funk F, Rakov V, et al. Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide. Curr Drug Metab 2014; 15: 953-965
17. Geisser P, Philipp E. PA21: A novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 2010; 74: 4-11
18. Ficociello L, Ma L, Parameswaran V, et al. Real-world use of sucroferric oxyhydroxide and hemodialysis patients: Changes in the serum phosphorus control and phosphate binder pill burden, 2015, Poster presented at American Society of Nephrology AnnualMeeting 2015. Abstract 37
19. Lee CT, Wu IW, Chiang SS, et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: Multicenter, randomized, double-blind, placebo-controlled study. J Nephrol 2015; 28: 105-113
20. Yokoyama K, Akiba T, Fukagawa M, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant 2014; 29: 1053-1060
21. Yokoyama K, Akiba T, FukagawaMet al. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. J RenNutr 2014; 24: 261-267
22. Lewis JB, Sika M, Koury MJ, et al. Collaborative Study Group: Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 2015; 26: 493-503
23. Umanath K, Jalal DI, Greco BA, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ERSD. J Am Soc Nephrol 2015; 26: 2578-2587
24. Velphoro(R) (sucroferric oxyhydroxide) Prescribing Information 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205109s001lbl.pdf (June 2016, date last accessed)
25. Salovaara S, Sandberg AS, Andlid T. Combined impact of pH and organic acids on iron uptake by Caco-2 cells. J Agric Food Chem 2003; 51: 7820-7824
26. Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals 2014; 7: 990-998
27. Cada DJ, Cong J, Baker DE. Ferric citrate. Hosp Pharm2015; 50: 139-151